Early Life and Education
Hubertus von Baumbach, born in 1967, is a German businessman and a member of the von Baumbach family, which has been involved in Boehringer Ingelheim for generations. He is a great-grandson of the company's founder, Albert Boehringer. Von Baumbach's early life was marked by a strong educational foundation, including a law degree and an MBA from the Massachusetts Institute of Technology (MIT) Sloan School of Management. He also completed a banking apprenticeship.
Rise to Success
Von Baumbach's career began in 1998 at F. Hoffmann-La Roche AG in the US affiliate. He joined Boehringer Ingelheim in 2001. He held various leadership positions in Finance & Controlling. In 2009, he became the CFO, and in June 2016, he was appointed as the Chairman and CEO of Boehringer Ingelheim. During his tenure, von Baumbach has overseen significant strategic moves, including an asset swap deal with Sanofi and a reorganization to give the group a more decentralized structure.
Key Business Strategies
Boehringer Ingelheim, under von Baumbach's leadership, has focused on innovation in human pharmaceuticals, animal health, and biopharmaceuticals. The company has been investing heavily in research and development, with expenditures reaching approximately EUR 6.2 billion in 2024. The company has a strong pipeline, with several therapies nearing regulatory approval. The company is on track to launch up to 20 new treatments in Human Pharma by 2030, and 20 additional opportunities in Animal Health by 2026.
Philanthropy
While specific figures for von Baumbach's personal philanthropy are not readily available, Boehringer Ingelheim is involved in various initiatives, particularly in stroke care and animal health. The company supports the Angels Initiative for stroke care and is dedicated to the well-being of animals and people through its animal health division.